325 related articles for article (PubMed ID: 28521698)
21. Metal compounds for the treatment of parasitic diseases.
Fricker SP; Mosi RM; Cameron BR; Baird I; Zhu Y; Anastassov V; Cox J; Doyle PS; Hansell E; Lau G; Langille J; Olsen M; Qin L; Skerlj R; Wong RS; Santucci Z; McKerrow JH
J Inorg Biochem; 2008 Oct; 102(10):1839-45. PubMed ID: 18684510
[TBL] [Abstract][Full Text] [Related]
22. Repositioning of leishmanicidal [1,2,3]Triazolo[1,5-a]pyridinium salts for Chagas disease treatment: Trypanosoma cruzi cell death involving mitochondrial membrane depolarisation and Fe-SOD inhibition.
Martín-Escolano R; Martín-Escolano J; Ballesteros-Garrido R; Cirauqui N; Abarca B; Rosales MJ; Sánchez-Moreno M; Ballesteros R; Marín C
Parasitol Res; 2020 Sep; 119(9):2943-2954. PubMed ID: 32607710
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy of leishmaniasis part III: synthesis and bioevaluation of novel aryl substituted terpenyl pyrimidines as antileishmanial agents.
Chandra N; Pandey S; Ramesh ; Suryawanshi SN; Gupta S
Eur J Med Chem; 2006 Jun; 41(6):779-85. PubMed ID: 16697490
[TBL] [Abstract][Full Text] [Related]
24. Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review.
Santos SS; de Araújo RV; Giarolla J; Seoud OE; Ferreira EI
Int J Antimicrob Agents; 2020 Apr; 55(4):105906. PubMed ID: 31987883
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.
Khare S; Nagle AS; Biggart A; Lai YH; Liang F; Davis LC; Barnes SW; Mathison CJ; Myburgh E; Gao MY; Gillespie JR; Liu X; Tan JL; Stinson M; Rivera IC; Ballard J; Yeh V; Groessl T; Federe G; Koh HX; Venable JD; Bursulaya B; Shapiro M; Mishra PK; Spraggon G; Brock A; Mottram JC; Buckner FS; Rao SP; Wen BG; Walker JR; Tuntland T; Molteni V; Glynne RJ; Supek F
Nature; 2016 Sep; 537(7619):229-233. PubMed ID: 27501246
[TBL] [Abstract][Full Text] [Related]
26. Bisphosphonate-Based Molecules as Potential New Antiparasitic Drugs.
Branco Santos JC; de Melo JA; Maheshwari S; de Medeiros WMTQ; de Freitas Oliveira JW; Moreno CJ; Mario Amzel L; Gabelli SB; Sousa Silva M
Molecules; 2020 Jun; 25(11):. PubMed ID: 32503272
[TBL] [Abstract][Full Text] [Related]
27. Individual and combined antiparasitic effect of six plant metabolites against Leishmania amazonensis and Trypanosoma cruzi.
Sandjo LP; de Moraes MH; Kuete V; Kamdoum BC; Ngadjui BT; Steindel M
Bioorg Med Chem Lett; 2016 Apr; 26(7):1772-5. PubMed ID: 26906638
[TBL] [Abstract][Full Text] [Related]
28. Computer-Aided Drug Design Using Sesquiterpene Lactones as Sources of New Structures with Potential Activity against Infectious Neglected Diseases.
Herrera Acevedo C; Scotti L; Feitosa Alves M; Formiga Melo Diniz MF; Scotti MT
Molecules; 2017 Jan; 22(1):. PubMed ID: 28054952
[TBL] [Abstract][Full Text] [Related]
29. Innovative lead compounds and formulation strategies as newer kinetoplastid therapies.
Espuelas S; Plano D; Nguewa P; Font M; Palop JA; Irache JM; Sanmartín C
Curr Med Chem; 2012; 19(25):4259-88. PubMed ID: 22834813
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Potential of Flavonoid Derivatives for Certain Neglected Tropical Diseases.
Pone BK; Ferreira EI
Curr Drug Targets; 2022; 23(7):680-682. PubMed ID: 35264087
[TBL] [Abstract][Full Text] [Related]
31. Leishmanicidal and trypanocidal potential of the essential oil of
Cortez Sombra Vandesmet L; Almeida de Menezes S; Machado Portela BY; Gomes Vidal Sampaio M; Bezerra Dos Santos CR; Luiz Lermen V; Gomez MCV; Silva MVD; de Alencar Menezes IR; Dos Santos Correia MT
Nat Prod Res; 2022 Feb; 36(4):1038-1042. PubMed ID: 33207966
[TBL] [Abstract][Full Text] [Related]
32. Novel selective inhibitor of Leishmania (Leishmania) amazonensis arginase.
da Silva ER; Boechat N; Pinheiro LC; Bastos MM; Costa CC; Bartholomeu JC; da Costa TH
Chem Biol Drug Des; 2015 Nov; 86(5):969-78. PubMed ID: 25845502
[TBL] [Abstract][Full Text] [Related]
33. Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis.
Marr JJ
J Lab Clin Med; 1991 Aug; 118(2):111-9. PubMed ID: 1906917
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo antiparasital activity against Trypanosoma cruzi of three novel 5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7(4H)-one-based complexes.
Caballero AB; Marín C; Rodríguez-Diéguez A; Ramírez-Macías I; Barea E; Sánchez-Moreno M; Salas JM
J Inorg Biochem; 2011 Jun; 105(6):770-6. PubMed ID: 21497152
[TBL] [Abstract][Full Text] [Related]
35. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents.
Werbovetz K
Curr Opin Investig Drugs; 2006 Feb; 7(2):147-57. PubMed ID: 16499285
[TBL] [Abstract][Full Text] [Related]
36. SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents.
Gigante F; Kaiser M; Brun R; Gilbert IH
Bioorg Med Chem; 2009 Aug; 17(16):5950-61. PubMed ID: 19620005
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and antileishmanial profile of some novel terpenyl pyrimidines.
Pandey S; Suryawanshi SN; Gupta S; Srivastava VM
Eur J Med Chem; 2004 Nov; 39(11):969-73. PubMed ID: 15501546
[TBL] [Abstract][Full Text] [Related]
38. In vitro anti-leishmania evaluation of nickel complexes with a triazolopyrimidine derivative against Leishmania infantum and Leishmania braziliensis.
Ramírez-Macías I; Maldonado CR; Marín C; Olmo F; Gutiérrez-Sánchez R; Rosales MJ; Quirós M; Salas JM; Sánchez-Moreno M
J Inorg Biochem; 2012 Jul; 112():1-9. PubMed ID: 22542591
[TBL] [Abstract][Full Text] [Related]
39. New uses for old complexes: The very first report on the trypanocidal activity of symmetric trinuclear ruthenium complexes.
Possato B; Carneiro ZA; de Albuquerque S; Nikolaou S
J Inorg Biochem; 2017 Nov; 176():156-158. PubMed ID: 28915432
[TBL] [Abstract][Full Text] [Related]
40. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis.
Alcântara LM; Ferreira TCS; Gadelha FR; Miguel DC
Int J Parasitol Drugs Drug Resist; 2018 Dec; 8(3):430-439. PubMed ID: 30293058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
